id stringlengths 9 11 | source stringclasses 1
value | title stringlengths 15 560 | text stringlengths 2k 153k |
|---|---|---|---|
PMC4744665 | core_pubmed_pmc | Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures | Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures Abstract Summary The antiepileptic drug ( AED ) perampanel is approved in ≥40 countries as adjunctive therapy for drug‐resistant partial seizures in patients with epilepsy. This post hoc anal... |
PMC12366529 | core_pubmed_pmc | Pharmacokinetics and metabolism of artemisinin (ART) in Plasmodium yoelii : ART-heme adduct as a potential biomarker for its resistance | Pharmacokinetics and metabolism of artemisinin (ART) in Plasmodium yoelii : ART-heme adduct as a potential biomarker for its resistance Abstract Abstract Background Plasmodium falciparum in Southeast Asia and Africa is developing resistance to the antimalarial drug artemisinin (ART). In this study, the metabolite of AR... |
PMC11061366 | core_pubmed_pmc | Target-controlled infusion of remimazolam effect-site concentration for total intravenous anesthesia in patients undergoing minimal invasive surgeries | Target-controlled infusion of remimazolam effect-site concentration for total intravenous anesthesia in patients undergoing minimal invasive surgeries Abstract Abstract Background Although pharmacokinetic and pharmacodynamic models of remimazolam have been developed, their clinical application remains limited. This stu... |
PMC12296837 | core_pubmed_pmc | Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors | Phase-Ib dose-finding and pharmacokinetic trial of metformin combined with nivolumab for refractory/recurrent solid tumors Abstract Background Our previous findings showed that the addition of metformin to nivolumab resulted in remarkable tumor regression and increased the number of tumor-infiltrating T cells in mouse ... |
PMC8455987 | core_pubmed_pmc | Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels | Pharmacokinetic, Clinical, and Myeloid Marker Responses to Acepromazine Sedation in Arabian Camels Abstract Sedatives and tranquilizers are important in the control of excited camels during camel transport. This study was conducted to investigate the clinical sedation of camels with acepromazine and its correlation wit... |
PMC11206778 | core_pubmed_pmc | Preclinical Pharmacokinetic Study and Lung Penetration of a Coumarin Extracted from Zanthoxylum tingoassuiba | Preclinical Pharmacokinetic Study and Lung Penetration of a Coumarin Extracted from Zanthoxylum tingoassuiba Abstract Abstract The compound 6-methoxyseselin, derived from Zanthoxylum tingoassuiba , demonstrates various therapeutic properties, including vasorelaxation, antinociceptive, anti-inflammatory, and immunomodul... |
PMC12306225 | core_pubmed_pmc | Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors | Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors Abstract Abstract Background There is an unmet need for novel immunotherapies to overcome immune evasion in patients with advanced skin cancers resistant to pr... |
PMC3130141 | core_pubmed_pmc | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors Abstract Introduction AZD4877 is a potent Eg5 inhibitor that has been shown to have an acceptable tolerability profile in a Phase I study of Western patients with solid tumors. This study was conducte... |
PMC12045430 | core_pubmed_pmc | Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer | Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate Cancer Abstract Purpose: Castration and enzalutamide induce BCL-2 to drive therapy resistance in prostate cancer (PCa). We conducted a phase Ib trial to test that metastatic castration-resistant PCa (mCRPC) can be e... |
PMC4837593 | core_pubmed_pmc | A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol | A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol Abstract Background Metronomic oral vinorelbine is effective in metastatic NSCLC and malignant pleural mesot... |
PMC8820988 | core_pubmed_pmc | Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI Rx in Patients With ESRD | Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI Rx in Patients With ESRD Abstract Introduction Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXI Rx is a novel strategy that... |
PMC6986528 | core_pubmed_pmc | Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration | Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration Abstract BACKGROUND: Parkinson’s disease is one of the most common neurological diseases. Pathogenesis of the disease is associated with destruction and death of neurons that produce the neurotransmitter dopamine. The precursor to dopamine, whi... |
PMC7109194 | core_pubmed_pmc | Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies | Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies Abstract Abstract Background and objectives Blinatumomab (BLINCYTO ® ) is a novel bispecific T cell engager (BiTE ® ) approved in the USA for the treatment of relapsed or refractory B cell precursor acute lymphob... |
PMC5297985 | core_pubmed_pmc | A Steady‐State Head‐to‐Head Pharmacokinetic Comparison of All FK‐506 (Tacrolimus) Formulations (ASTCOFF): An Open‐Label, Prospective, Randomized, Two‐Arm, Three‐Period Crossover Study | A Steady‐State Head‐to‐Head Pharmacokinetic Comparison of All FK‐506 (Tacrolimus) Formulations (ASTCOFF): An Open‐Label, Prospective, Randomized, Two‐Arm, Three‐Period Crossover Study Abstract This two‐sequence, three‐period crossover study is the first pharmacokinetic ( PK ) study to compare all three innovator formul... |
PMC12351435 | core_pubmed_pmc | Pharmacokinetic Prediction and Cytotoxicity of New Quercetin Derivatives | Pharmacokinetic Prediction and Cytotoxicity of New Quercetin Derivatives Abstract ABSTRACT Quercetin (QUE) possesses various pharmacological properties; however, its low bioavailability and solubility hinder its beneficial effects. Enzymatic glycosylation has been explored to improve these aspects. In the present study... |
PMC9909315 | core_pubmed_pmc | SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells | SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells Abstract Abstract Focal adhesion kinase (FAK), a multi-functional cytoplasmic tyrosine kinase, plays a critical role in cancer migration, proliferation and metastasis via regulating multiple signaling pathways. SY-707 is an anap... |
PMC8911105 | core_pubmed_pmc | Effects of 1α,25-dihydroxyvitamin D 3 on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats | Effects of 1α,25-dihydroxyvitamin D 3 on the pharmacokinetics and biodistribution of ergothioneine, an endogenous organic cation/carnitine transporter 1 substrate, in rats Abstract Abstract Purpose This study aimed to investigate the effects of 1α,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) on the expression levels of or... |
PMC6178753 | core_pubmed_pmc | Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study | Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study Abstract Abstract Background Due to a paucity of data on the efficacy and safety of direct oral anticoagulants ( DOAC s) in patients with a body mass index >40 kg/m 2 or a weight >120 kg, the use... |
PMC5829874 | core_pubmed_pmc | Computerised decision to reduce inappropriate medication in the elderly: a systematic review with meta-analysis protocol | Computerised decision to reduce inappropriate medication in the elderly: a systematic review with meta-analysis protocol Abstract Introduction Life expectancy continues to increase in developed countries. Elderly people are more likely to consume more medications and become vulnerable to age-related changes in drugs’ p... |
PMC10302868 | core_pubmed_pmc | Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents | Assessing Boron-Pleuromutilin AN11251 for the Development of Antibacterial Agents Abstract Pleuromutilins are a group of antibiotics derived from the naturally occurring compound. The recent approval of lefamulin for both intravenous and oral doses in humans to treat community-acquired bacterial pneumonia has prompted ... |
PMC7670852 | core_pubmed_pmc | Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy | Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy Abstract Abstract Clopidogrel is the most common and widely used antiplatelet agent for patients with coronary artery disease following confirmation by electrocardiographic studies. The nonresponsiveness of patients to clopidogr... |
PMC9782767 | core_pubmed_pmc | Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview | Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview Abstract Natural medicine has been widely used for clinical treatment and health care in many countries and regions. Additionally, extracting active ingredients from traditional Chinese medicine and o... |
PMC8796384 | core_pubmed_pmc | Plasma protein binding prediction focusing on residue-level features and circularity of cyclic peptides by deep learning | Plasma protein binding prediction focusing on residue-level features and circularity of cyclic peptides by deep learning Abstract Abstract Motivation In recent years, cyclic peptide drugs have been receiving increasing attention because they can target proteins that are difficult to be tackled by conventional small-mol... |
PMC10578023 | core_pubmed_pmc | A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways | A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways Abstract Abstract Background As a member of the Janus kinase (JAK) family, which includes JAK1, JAK2 and JAK3, tyrosine kinase 2 (TYK2) plays an important role in signal transduction and imm... |
PMC11132652 | core_pubmed_pmc | Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly | Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly Abstract Abstract The primary goal of acromegaly treatment is to normalize biochemical parameters as it significantly reduces the risks of complications and comorbidities associated with the disease. First-line medical treatment is common... |
PMC10475848 | core_pubmed_pmc | Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial | Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial Abstract Abstract Background Niemann-Pick disease type C (NPC) is a rare... |
PMC5405391 | core_pubmed_pmc | Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management | Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management Abstract Despite increased awareness of the potential of herb-drug interactions (HDIs), the lack of rigorous clinical evi... |
PMC3346975 | core_pubmed_pmc | Pharmacokinetics of Ganoderic Acids A and F after Oral Administration of Ling Zhi Preparation in Healthy Male Volunteers | Pharmacokinetics of Ganoderic Acids A and F after Oral Administration of Ling Zhi Preparation in Healthy Male Volunteers Abstract Abstract The objectives of this paper were to evaluate the pharmacokinetics of ganoderic acids A and F after a single oral dose of the water extract of MG2-strain Ling Zhi (MG2FB-WE) and to ... |
PMC9675287 | core_pubmed_pmc | Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma | Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma Abstract Background Eosinophilic asthma is a common subtype of severe asthma with high morbidity and mortality. The cytokine IL-5 has been shown to be a key driver of the development and progre... |
PMC8889168 | core_pubmed_pmc | Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics | Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics Abstract Abstract Non-clinical models to study metabolism including animal models and cell assays are often limited in terms of species translatability and predictability of human biology. This field urgen... |
PMC12135518 | core_pubmed_pmc | Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients | Population pharmacokinetics and dosing optimization of teicoplanin in renal transplant patients Abstract ABSTRACT The objectives of this study were to investigate the population pharmacokinetic (PK) characteristics of teicoplanin in renal transplant patients and to provide recommendations for optimal teicoplanin dosing... |
PMC9303693 | core_pubmed_pmc | Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment | Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment Abstract Abstract Acalabrutinib received approval for the treatment of adult patients with mantle cell lymphoma who received at least 1 prior therapy and adult patients with chronic lymphocytic leukemia o... |
PMC3931937 | core_pubmed_pmc | Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors | Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors Abstract Purpose Patritumab (U3-1287) is a human epidermal growth factor receptor-3 (HER3)-targeted antibody that blocks ligand-associated activation of HER3. This open-lab... |
PMC10587432 | core_pubmed_pmc | PK-PD integration of enrofloxacin and cefquinome alone and in combination against Klebsiella pneumoniae using an in vitro dynamic model | PK-PD integration of enrofloxacin and cefquinome alone and in combination against Klebsiella pneumoniae using an in vitro dynamic model Abstract Introduction: Klebsiella pneumoniae is classified as a critical pathogen in both animals and humans and infections can be fatal in chickens resulting in substantial economic l... |
PMC10471475 | core_pubmed_pmc | Evaluating the activity of N-89 as an oral antimalarial drug | Evaluating the activity of N-89 as an oral antimalarial drug Abstract Despite the recent progress in public health measures, malaria remains a troublesome disease that needs to be eradicated. It is essential to develop new antimalarial medications that are reliable and secure. This report evaluated the pharmacokinetics... |
PMC11680423 | core_pubmed_pmc | Comparison of Ketamine/Diazepam and Tiletamine/Zolazepam Combinations for Anaesthesia Induction in Horses Undergoing Partial Intravenous Anaesthesia (PIVA): A Retrospective Clinical Study | Comparison of Ketamine/Diazepam and Tiletamine/Zolazepam Combinations for Anaesthesia Induction in Horses Undergoing Partial Intravenous Anaesthesia (PIVA): A Retrospective Clinical Study Abstract Simple Summary The induction of general anaesthesia in horses is commonly achieved with a dissociative anaesthetic, usually... |
PMC11847724 | core_pubmed_pmc | An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors | An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors Abstract Highlights • Anaplastic lymphoma kinase (ALK) dysregulation is implicated in numerous cancers. • ESK-440 uses a novel strategy to target cancers resist... |
PMC9285676 | core_pubmed_pmc | Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study | Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study Abstract Abstract Multicenter, prospective, observational study to compare the relative bioavailability of once‐daily tacrolimus formulations in de novo kidney tran... |
PMC8345584 | core_pubmed_pmc | Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel | Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel Abstract Abstract Simple Summary This study investigated the correlation between scalp cooling used to prevent chemotherapy-induced alopecia and the pharmacokinetics of paclitaxel in female cancer patients with a solid tumor. In a prospective cohort study, 1... |
PMC7456803 | core_pubmed_pmc | Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (M pro ): A computational study | Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (M pro ): A computational study Abstract Highlights • Four Azo imidazole derivatives (L1-L4) have been synthesized and characterized by different spectroscopic and analytical tools. • The inhibitory potential of the derivatives... |
PMC11227858 | core_pubmed_pmc | Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial | Pharmacokinetics and Safety of Oliceridine Fumarate Injection in Chinese Patients with Chronic Non-Cancer Pain: A Phase I, Single-Ascending-Dose, Open-Label Clinical Trial Abstract Abstract Background Oliceridine is a novel G protein‐biased ligand μ-opioid receptor agonist. This study aimed to assess the pharmacokineti... |
PMC12009037 | core_pubmed_pmc | Parametric Population Pharmacokinetics Model Repository of Rifampicin: Model-Informed Individualized Therapy | Parametric Population Pharmacokinetics Model Repository of Rifampicin: Model-Informed Individualized Therapy Abstract Introduction Rifampicin is a crucial first-line anti-tuberculosis drug that has been extensively studied through population pharmacokinetic (popPK) analyses. This study aims to construct a comprehensive... |
PMC8929268 | core_pubmed_pmc | Principles of empiric antimicrobial usage and dosing: Lessons learned | Principles of empiric antimicrobial usage and dosing: Lessons learned Abstract Abstract A lack of clinical response to empiric antimicrobials behooves the clinician to reflect further on diagnostic considerations. When prescribing antibiotics, determining the correct dose, most optimal route of administration, and cons... |
PMC12664286 | core_pubmed_pmc | In Vitro and In Vivo Evaluation of Rosuvastatin and Momordica charantia ( Bitter Melon ) Extract: Pharmacokinetic Interactions and Anticancer Potential | In Vitro and In Vivo Evaluation of Rosuvastatin and Momordica charantia ( Bitter Melon ) Extract: Pharmacokinetic Interactions and Anticancer Potential Abstract Abstract Objective: This study investigates the pharmacokinetic interactions and anticancer potential for rosuvastatin in combination with Momordica charantia ... |
PMC12124858 | core_pubmed_pmc | Thymoquinone loaded on chitosan nanoparticles alleviated the consequences of cryptosporidiosis infection in a murine model: Evidence from parasitological, histopathological, immunohistochemical, and immunological studies | Thymoquinone loaded on chitosan nanoparticles alleviated the consequences of cryptosporidiosis infection in a murine model: Evidence from parasitological, histopathological, immunohistochemical, and immunological studies Abstract Abstract Background Cryptosporidiosis, a parasitic zoonosis caused by the genus Cryptospor... |
PMC8426389 | core_pubmed_pmc | In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance | In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance Abstract Abstract In a biologic therapeutic landscape that requires versatility in targeting specificity, valency and half-life modulation, the monomeric Fc fusion platform holds exciting potential for the ... |
PMC12214877 | core_pubmed_pmc | 18 F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors | 18 F-FLT PET, a Noninvasive Pharmacodynamic Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK) Inhibitors Abstract Abstract A dysregulated cell cycle is a hallmark of cancer and inhibition of cyclin-dependent kinases (CDK) is a proven therapeutic strategy in t... |
PMC6108829 | core_pubmed_pmc | Physiologically Based Pharmacokinetic (PBPK) Modeling of the Bisphenols BPA, BPS, BPF, and BPAF with New Experimental Metabolic Parameters: Comparing the Pharmacokinetic Behavior of BPA with Its Substitutes | Physiologically Based Pharmacokinetic (PBPK) Modeling of the Bisphenols BPA, BPS, BPF, and BPAF with New Experimental Metabolic Parameters: Comparing the Pharmacokinetic Behavior of BPA with Its Substitutes Abstract Background: The endocrine disrupting chemical bisphenol A (BPA) has been facing stricter regulations in ... |
PMC6470777 | core_pubmed_pmc | A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine | A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine Abstract Astragali radix (AR) is one of the most widely used traditional Chinese herbal medicines. Modern pharmacological studies and clinical practices indicate that ... |
PMC3896718 | core_pubmed_pmc | Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates | Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates Abstract Abstract Background Mirtazapine (MRZ) is a human antidepressant drug metabolized to 8-OH mirtazapine (8-OH) and dimethylmirtazapine (DMR) metabolites. Recently, this drug has bee... |
PMC11035504 | core_pubmed_pmc | Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects | Pharmacokinetic and Safety Study of Bismuth Potassium Citrate Formulations in Healthy Subjects Abstract Abstract Background Potassium bismuth citrate is a gastric mucosal protector and a key drug for treating peptic ulcers. Objective To evaluate the pharmacokinetic characteristics and safety of 120-mg bismuth potassium... |
PMC6354606 | core_pubmed_pmc | Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues | Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues Abstract Abstract Purpose: To explore the ocular distribution of bimatoprost after intracameral administration of a biodegradable sustained-release bimatoprost implant (Bimatoprost ... |
PMC8064372 | core_pubmed_pmc | Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review | Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review Abstract Vancomycin is commonly used as a treatment for neonatal infections. However, there is a lack of consensus establishing the optimal vancomycin therapeutic regimen and defining the most appropriate PK/PD parameter correlated wi... |
PMC11993298 | core_pubmed_pmc | Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients | Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients Abstract OATP1B, P‐gp, BCRP, and CYP3A are the most contributing drug‐metabolizing enzymes or transporters (DMETs) for commonly prescribed medication. Their activities may chan... |
PMC9700266 | core_pubmed_pmc | Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation | Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation Abstract Summary Background The initial dose of tacrolimus after liver transplantation (LT) is critical for rapidly achieving the steady state of the drug concentration, minimizing the potential adverse reacti... |
PMC6704523 | core_pubmed_pmc | Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial | Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial Abstract Background The anti–interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patien... |
PMC10044431 | core_pubmed_pmc | Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria | Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria Abstract Abstract Critically ill patients suffering from severe infections are prone to pathophysiological pharmacokinetic changes that are frequen... |
PMC9142470 | core_pubmed_pmc | A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis | A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis Abstract Background Ruxolitinib cream is a topical formulation of ruxolitinib, an inhibitor of Janus kinase 1 and Janus kinase 2. Objective We aimed to determine the safety, tolerability, and bioavailability of 1.5% ruxolitinib cr... |
PMC3614726 | core_pubmed_pmc | Non-Markovian Population Dynamics: Does it Help to Optimize the Chemotherapeutic Strategy? | Non-Markovian Population Dynamics: Does it Help to Optimize the Chemotherapeutic Strategy? Abstract A non-Markovian theory of population dynamics is to simulate the anti-cancer drug distribution between malignant and the hosting normal cell pools. The model takes into account both the cell life span and the proliferati... |
PMC12856967 | core_pubmed_pmc | A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants | A Phase 1, Randomized, Open‐Label, Parallel Group Study to Evaluate the Relative Bioavailability and Safety of Subcutaneous Bepirovirsen when Delivered from a Vial or Prefilled Syringe Fitted with a Safety Syringe Device in Healthy Adult Participants Abstract Abstract Bepirovirsen, an antisense oligonucleotide in devel... |
PMC9102708 | core_pubmed_pmc | Cardiopulmonary Effects and Pharmacokinetics of Dexmedetomidine Used as an Adjunctive Analgesic to Regional Anesthesia of the Oral Cavity with Levobupivacaine in Dogs | Cardiopulmonary Effects and Pharmacokinetics of Dexmedetomidine Used as an Adjunctive Analgesic to Regional Anesthesia of the Oral Cavity with Levobupivacaine in Dogs Abstract Abstract Simple Summary The modern approach to multimodal analgesia is based on the use of various types of analgesics before, during, and after... |
PMC6024415 | core_pubmed_pmc | First 18 F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo | First 18 F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo Abstract Abstract In vivo quantification of CXCR4 expression using [ 68 Ga]pentixafor for positron emission tomography (PET) imaging has gained significant clinical interest as CXCR4 plays a fundamental role in oncology and po... |
PMC11879232 | core_pubmed_pmc | Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study | Population pharmacokinetic analysis of teicoplanin in paediatric patients, including those receiving continuous kidney replacement therapy: a prospective cohort study Abstract Abstract Objectives Teicoplanin is a commonly used antibiotic in critically ill children. However, teicoplanin dosing is often inaccurate, espec... |
PMC7170501 | core_pubmed_pmc | Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecific and trafficking of adoptively transferred T cells in mouse xenograft model | Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecific and trafficking of adoptively transferred T cells in mouse xenograft model Abstract P-cadherin-LP-DART is a bispecific antibody targeting P-cadherin expressed on the tumor cells and CD3 on the T-cells. Previously we demonstrated the development ... |
PMC9332635 | core_pubmed_pmc | Development and validation of an LC–MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies | Development and validation of an LC–MS/MS method for quantification of NC-8 in rat plasma and its application to pharmacokinetic studies Abstract Abstract ent -16-Oxobeyeran-19- N -methylureido (NC-8) is a recently synthesized derivative of iso-steviol that showed anti-hepatitis B virus (HBV) activity by disturbing rep... |
PMC9599119 | core_pubmed_pmc | The Effect of Menopause on Antipsychotic Response | The Effect of Menopause on Antipsychotic Response Abstract Abstract Background : It has been hypothesized that, whenever estrogen levels decline, psychosis symptoms in women increase. At menopause, this can happen in two main ways: (a) the loss of estrogen (mainly estradiol) can directly affect central neurotransmissio... |
PMC8007522 | core_pubmed_pmc | Assessment of Drug Delivery Kinetics to Epidermal Targets In Vivo | Assessment of Drug Delivery Kinetics to Epidermal Targets In Vivo Abstract Abstract It has proven challenging to quantify ‘drug input’ from a formulation to the viable skin because the epidermal and dermal targets of topically applied drugs are difficult, if not impossible, to access in vivo . Defining the drug input f... |
PMC4734792 | core_pubmed_pmc | Miconazole-loaded solid lipid nanoparticles: formulation and evaluation of a novel formula with high bioavailability and antifungal activity | Miconazole-loaded solid lipid nanoparticles: formulation and evaluation of a novel formula with high bioavailability and antifungal activity Abstract Abstract Background and objective Miconazole is a broad-spectrum antifungal drug that has poor aqueous solubility (<1 µg/mL); as a result, a reduction in its therapeutic ... |
PMC5368956 | core_pubmed_pmc | A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers | A phase 1 study comparing the proposed biosimilar BS‐503a with bevacizumab in healthy male volunteers Abstract Abstract This is a randomized, double‐blind, single‐dose, parallel group phase 1 study to assess pharmacokinetic similarity, safety, and tolerability of BS‐503a, a proposed bevacizumab biosimilar. A total of 1... |
PMC6272591 | core_pubmed_pmc | Preparation, Characterization and Pharmacokinetic Study of Xiangfu Siwu Decoction Essential Oil/β-Cyclodextrin Inclusion Complex | Preparation, Characterization and Pharmacokinetic Study of Xiangfu Siwu Decoction Essential Oil/β-Cyclodextrin Inclusion Complex Abstract Abstract Xiang-Fu-Si-Wu Decoction (XFSWD), a famous Chinese herbal formula, is considered an effective prescription for treating primary dysmenorrhea. The essential oil is a signific... |
PMC12635088 | core_pubmed_pmc | Antibacterial potential and in silico analysis of inflorescence-derived essential oils from three Eucalyptus species | Antibacterial potential and in silico analysis of inflorescence-derived essential oils from three Eucalyptus species Abstract Abstract Inflorescences represent a relatively underexplored source of essential oils (EOs); this investigation explores the chemical composition of three Eucalyptus species cultivated in Tunisi... |
PMC11531078 | core_pubmed_pmc | Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial | Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trial Abstract Background: Zuranolone is an oral, once-daily, 14-day treatment course approved for adults with postpartum depression in the United States. Aims: To assess cogniti... |
PMC12110724 | core_pubmed_pmc | Pharmacokinetics and Pharmacodynamics of Intravenous Magnesium Sulfate in Pediatric Acute Asthma Exacerbations | Pharmacokinetics and Pharmacodynamics of Intravenous Magnesium Sulfate in Pediatric Acute Asthma Exacerbations Abstract Abstract Pediatric asthma exacerbations represent a significant cause of emergency department use and hospitalizations. Despite available treatment options, many children's exacerbations are refractor... |
PMC11359822 | core_pubmed_pmc | Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing | Next-Generation Contraceptive Intravaginal Ring: Comparison of Etonogestrel and Ethinyl Estradiol In Vitro and In Vivo Release from 3D-Printed Intravaginal Ring and NuvaRing Abstract Abstract Intravaginal rings (IVRs) represent a well-established, woman-controlled and sustained vaginal drug delivery system suitable for... |
PMC8935840 | core_pubmed_pmc | Exploring ITM2A as a new potential target for brain delivery | Exploring ITM2A as a new potential target for brain delivery Abstract Background Integral membrane protein 2A (ITM2A) is a transmembrane protein expressed in a variety of tissues; little is known about its function, particularly in the brain. ITM2A was found to be highly enriched in human brain versus peripheral endoth... |
PMC4791481 | core_pubmed_pmc | A strategy for residual error modeling incorporating scedasticity of variance and distribution shape | A strategy for residual error modeling incorporating scedasticity of variance and distribution shape Abstract Nonlinear mixed effects models parameters are commonly estimated using maximum likelihood. The properties of these estimators depend on the assumption that residual errors are independent and normally distribut... |
PMC12721660 | core_pubmed_pmc | Adherence to Hormonal Therapies in Prostate Cancer | Adherence to Hormonal Therapies in Prostate Cancer Abstract Abstract Introduction: Hormonal therapy is the standard of care in prostate cancer treatment. The approval of the first oral androgen deprivation therapy, relugolix, to treat prostate cancer patients provides an opportunity to review adherence to oral and inje... |
PMC9147553 | core_pubmed_pmc | Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach | Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach Abstract Abstract The revised consensus guidelines for optimizing vancomycin... |
PMC10964407 | core_pubmed_pmc | Liver sinusoidal cells eliminate blood-borne phage K1F | Liver sinusoidal cells eliminate blood-borne phage K1F Abstract ABSTRACT Phage treatment has regained attention due to an increase in multiresistant bacteria. For phage therapy to be successful, phages must reach their target bacteria in sufficiently high numbers. Blood-borne phages are believed to be captured by macro... |
PMC9665328 | core_pubmed_pmc | Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial | Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial Abstract Abstract Background CT‐P39 is being developed as a biosimilar of reference omalizumab. This study aimed to assess the pharmacokinetic equivalence of CT‐P39 to Europea... |
PMC7891569 | core_pubmed_pmc | Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing | Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing Abstract Abstract Natalizumab is approved for multiple sclerosis treatment at a dose of 300 mg every 4 weeks. Extended‐interval dosing of natalizumab has been proposed as a strategy to mit... |
PMC9395430 | core_pubmed_pmc | Synthesis, characterization, DFT, antioxidant, antibacterial, pharmacokinetics and inhibition of SARS-CoV-2 main protease of some heterocyclic hydrazones | Synthesis, characterization, DFT, antioxidant, antibacterial, pharmacokinetics and inhibition of SARS-CoV-2 main protease of some heterocyclic hydrazones Abstract Abstract Three hydrazone derivatives have been synthesized using condensation reaction of 4-hydrazinylbenzoic acid with three aromatic aldehydes namely: thio... |
PMC10864934 | core_pubmed_pmc | Bayesian estimation in NONMEM | Bayesian estimation in NONMEM Abstract Abstract Bayesian estimation is a powerful but underutilized tool for answering drug development questions. In this tutorial, the principles of Bayesian model development, assessment, and prior selection will be outlined. An example pharmacokinetic (PK) model will be used to demon... |
PMC5856296 | core_pubmed_pmc | Enhanced gastric therapeutic effects of Brucea javanica oil and its gastroretentive drug delivery system compared to commercial products in pharmacokinetics study | Enhanced gastric therapeutic effects of Brucea javanica oil and its gastroretentive drug delivery system compared to commercial products in pharmacokinetics study Abstract Background Brucea javanica oil (BJO), a traditional Chinese herbal medicine, has a variety of pharmacological activities and several BJO-related pat... |
PMC9022299 | core_pubmed_pmc | Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study | Optimization of levetiracetam dosing regimen in critically ill patients with augmented renal clearance: a Monte Carlo simulation study Abstract Background Levetiracetam pharmacokinetics is extensively altered in critically ill patients with augmented renal clearance (ARC). Consequently, the dosage regimens commonly use... |
PMC9859876 | core_pubmed_pmc | Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study | Examining the Systemic Bioavailability of Cannabidiol and Tetrahydrocannabinol from a Novel Transdermal Delivery System in Healthy Adults: A Single-Arm, Open-Label, Exploratory Study Abstract Abstract Introduction Transdermal cannabinoids may provide better safety and bioavailability profiles compared with other routes... |
PMC4157014 | core_pubmed_pmc | Metabolite Parameters as an Appropriate Alternative Approach for Assessment of Bioequivalence of Two Verapamil Formulations | Metabolite Parameters as an Appropriate Alternative Approach for Assessment of Bioequivalence of Two Verapamil Formulations Abstract A bioequivalence study of two verapamil formulations (generic verapamil tablets and Isoptin ® tablets) was performed by comparing pharmacokinetic parameters of the parent drug and its maj... |
PMC11084975 | core_pubmed_pmc | The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells | The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells Abstract Abstract Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients treated with EGFR–tyrosine kinase inhibitors ... |
PMC8241195 | core_pubmed_pmc | Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption | Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: in vitro aerosolization, histological examination and in vivo pulmonary absorption Abstract Abstract Bosentan is an endothelin receptor antagonist (ERA) prescribed for patients with pulmonary arterial hyper... |
PMC10445762 | core_pubmed_pmc | Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses | Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses Abstract Cannabidiol (CBD) products gain increasing popularity amongst animal owners and veterinarians as an alternative remedy for treatment of stress, inflammation or pain in horses. Whilst the use of cannab... |
PMC7006978 | core_pubmed_pmc | Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future | Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future Abstract Abstract Pharmacogenetic testing is a useful and increasingly widespread tool to assist in antidepressant prescription. More than ten antidepressants (including tricyclics, selective serotonin reuptake inhibitors and venlafaxine) h... |
PMC12415812 | core_pubmed_pmc | A Randomized, Blinded, Placebo‐Controlled Crossover Study of the Pharmacokinetics and Pharmacodynamics of Naloxone, Naltrexone, and Nalmefene in Methadone‐Sedated Working Dogs | A Randomized, Blinded, Placebo‐Controlled Crossover Study of the Pharmacokinetics and Pharmacodynamics of Naloxone, Naltrexone, and Nalmefene in Methadone‐Sedated Working Dogs Abstract ABSTRACT A randomized, blinded, placebo‐controlled crossover study was performed with eight professional working dogs to evaluate the p... |
PMC5117885 | core_pubmed_pmc | Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects | Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects Abstract CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor being developed for the treatment of dyslipidemia to raise high-density lipoprotein cholesterol. We investigated the safety, tole... |
PMC8504706 | core_pubmed_pmc | A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study | A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study Abstract Significance Statins are an important class of drugs that help to control hyperlipidemia, and one of these statins recently... |
PMC6631947 | core_pubmed_pmc | Cinnoline Scaffold—A Molecular Heart of Medicinal Chemistry? | Cinnoline Scaffold—A Molecular Heart of Medicinal Chemistry? Abstract Abstract The cinnoline nucleus is a very important bicyclic heterocycle that is used as the structural subunit of many compounds with interesting pharmaceutical properties. Cinnoline derivatives exhibit broad spectrum of pharmacological activities su... |
PMC4034589 | core_pubmed_pmc | Leveraging systems biology approaches in clinical pharmacology | Leveraging systems biology approaches in clinical pharmacology Abstract Computational modeling has been adopted in all aspects of drug research and development, from the early phases of target identification and drug discovery to the late-stage clinical trials. The different questions addressed during each stage of dru... |
PMC11762474 | core_pubmed_pmc | Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations | Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations Abstract Abstract In recent years, many population pharmacokinetic (popPK) models have been developed for echinocandins to bette... |
PMC4777343 | core_pubmed_pmc | Commonly Used Dietary Supplements on Coagulation Function during Surgery | Commonly Used Dietary Supplements on Coagulation Function during Surgery Abstract Abstract Abstract Background Patients who undergo surgery appear to use dietary supplements significantly more frequently than the general population. Because they contain pharmacologically active compounds, dietary supplements may affect... |
PMC11510160 | core_pubmed_pmc | Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework | Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK Framework Abstract Background/Objectives: Plasma levels of 4β-hydroxycholesterol (4β-OHC), a CYP3A-specific metabolite of cholesterol, are elevated after administrati... |
PMC12652451 | core_pubmed_pmc | Oral Delivery of a GI-Stable Apigenin–Cyclodextrin Complex via Pectin-Coated Nanoliposomes In Situ Gel: A DoE-Optimized Targeted Colon Cancer Therapy by Modulating Gut Drug Sensitivity | Oral Delivery of a GI-Stable Apigenin–Cyclodextrin Complex via Pectin-Coated Nanoliposomes In Situ Gel: A DoE-Optimized Targeted Colon Cancer Therapy by Modulating Gut Drug Sensitivity Abstract Abstract This study emphasizes overcoming the challenges of targeted drug delivery in colon cancer therapy by developing gastr... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.